Fig. 2: Effects of the CK2 inhibitor CX4945 on CK2 activity and cell viability in CCA cells.
From: The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells
a Cultured HUCCT-1 cells were treated with vehicle or the indicated concentrations of CX4945 for 6 h. Activity of CK2 in cell lysates was measured towards the CK2-specific peptide substrate. *p < 0.05 versus vehicle. b Cultured HUCCT-1 cells were treated with vehicle or the indicated concentrations of CX4945 for 6 h. 25 µg of proteins from total cell lysate were analyzed by western blot with the indicated antibodies. c, d CCA cells were treated with the indicated concentrations of CX4945 for 48 h. MTT assay was performed at end of the treatment. *p < 0.05 versus control
